Benzyl benzoate
Based on 1 publication(s) in Google Scholar
Benzyl benzoate (Phenylmethyl benzoate) is an orally active anti-scabies agent, acaricide (EC50= 0.06 g/m2) and fungicide. Benzyl benzoate is an angiotensin II (Ang II) inhibitor with antihypertensive effects. Benzyl benzoate can be used in perfumes, pharmaceuticals and the food industry.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.98%
- CAS. Nr.: 120-51-4
- Formel: C14H12O2
- Molecular Weight:212.25
-
Speicherung:
RT, protect from light.
In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) Benzyl benzoate
MoreAlle Endogenous Metabolite Isoform-spezifische Produkte anzeigen
MoreAlle Parasite Isoform-spezifische Produkte anzeigen
MoreAlle Angiotensin Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Mite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK-293T | IC50 |
107.2 μg/mL
Compound: 1
|
Antagonist activity at HA-tagged mouse AT1a angiotensin 2 receptor expressed in HEK293T cells assessed as decrease in angiotensin 2-induced intracellular calcium uptake
Antagonist activity at HA-tagged mouse AT1a angiotensin 2 receptor expressed in HEK293T cells assessed as decrease in angiotensin 2-induced intracellular calcium uptake
|
[PMID: 18672373] |
Benzyl benzoate (10000-50000 mg/L; 72 h) has toxic effects in allium root cells[3].
Benzyl benzoate (10-100 μM; 1-200 s) inhibits Ang II activity in a dose-dependent manner in 293T cells of human embryonic kidney epithelium (mAT1a(HA)/293T) (IC50=107 μg/mL) without cytotoxicity[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Benzyl benzoate (2-10 mg/kg; p.o.; Single dose) significantly inhibits Ang II (100 μg/kg) -induced hypertension in Std:ddY mice[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hypertensive male Std:ddY mice model[5]
-
Dosage:2 mg/kg, 10 mg/kg
-
Administration:Oral gavage (p.o.); Single dose. Before Ang II treatment (100 μg/kg; Intraperitoneal injection (i.p.); Single dose)
-
Result:Significantly inhibited the rise in systolic blood pressure induced by Ang II treatment.
-
Animal Model:Sprague Dawley male rats model[4]
-
Dosage:25 mg/kg, 100 mg/kg
-
Administration:Oral gavage (p.o.); Once daily for 90 days
-
Result:Induced hepatic portal vein blood supply, sinusoid sinus enlargement, monocyte infiltration, local lysis and cytoplasmic degeneration in rats.
Induced renal tissue congestion, renal tubule degeneration, monocyte infiltration and histolysis in rats. Resulted in increased number of Hassall’s bodies, elevated lipids, degeneration, congestion, fibrosis and lymphocytopenia in the thymus of rats.
Resulted in vacuolation and irregular secretion of the prostate in male reproductive system tissue, increased connective tissue of the epididymis and presence of cells in the lumen.
In the male reproductive system tissues, resulted in vacuolation and irregular secretion in the prostate, increased connective tissue of the epididymis, and presence of cells in the lumen.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 120-51-4
-
Appearance Liquid (Density: 1.118 g/cm3)
-
Molecular Weight 212.25
-
Formel C14H12O2
-
Color Colorless to light yellow
-
SMILES
O=C(OCC1=CC=CC=C1)C2=CC=CC=C2
-
Synonyms
Phenylmethyl benzoate
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
RT, protect from light
In solvent -80°C 1 year -20°C 6 months
Publications (1)
-
Journal Impact Factor
-
Most Recent
Lösungsmittel & Löslichkeit
DMSO : 200 mg/mL (942.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (11.78 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (11.78 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (278 KB)
-
SDS (597 KB)
- English - EN (597 KB)
- Français - FR (597 KB)
- Deutsch - DE (597 KB)
- Norwegian - NO (597 KB)
- Español - ES (597 KB)
- Swedish - SV (597 KB)
- Italian - IT (597 KB)
- Korean - KR (597 KB)
- Portuguese - PT (597 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Bachewar NP, et al. Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies. Indian J Pharmacol. 2009 Feb;41(1):9-14. [Content Brief]
[2]. Raynaud S, et al. Squamocin and benzyl benzoate, acaricidal components of Uvaria pauci-ovulata bark extracts. Planta Med. 2000 Mar;66(2):173-5. [Content Brief]
[4]. Kılıç Süloğlu A, et al. Toxicity of benzyl benzoate as a food additive and pharmaceutical agent. Toxicol Ind Health. 2022 Apr;38(4):221-233. [Content Brief]
[5]. Ohno O, et al. Inhibitory effects of benzyl benzoate and its derivatives on angiotensin II-induced hypertension. Bioorg Med Chem. 2008 Aug 15;16(16):7843-52. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.7114 mL | 23.5571 mL | 47.1143 mL | 117.7856 mL |
| 5 mM | 0.9423 mL | 4.7114 mL | 9.4229 mL | 23.5571 mL | |
| 10 mM | 0.4711 mL | 2.3557 mL | 4.7114 mL | 11.7786 mL | |
| 15 mM | 0.3141 mL | 1.5705 mL | 3.1410 mL | 7.8524 mL | |
| 20 mM | 0.2356 mL | 1.1779 mL | 2.3557 mL | 5.8893 mL | |
| 25 mM | 0.1885 mL | 0.9423 mL | 1.8846 mL | 4.7114 mL | |
| 30 mM | 0.1570 mL | 0.7852 mL | 1.5705 mL | 3.9262 mL | |
| 40 mM | 0.1178 mL | 0.5889 mL | 1.1779 mL | 2.9446 mL | |
| 50 mM | 0.0942 mL | 0.4711 mL | 0.9423 mL | 2.3557 mL | |
| 60 mM | 0.0785 mL | 0.3926 mL | 0.7852 mL | 1.9631 mL | |
| 80 mM | 0.0589 mL | 0.2945 mL | 0.5889 mL | 1.4723 mL | |
| 100 mM | 0.0471 mL | 0.2356 mL | 0.4711 mL | 1.1779 mL |